Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Healing Budz is a social healing platform created with the purpose of spreading kn...
Healing Budz is a social healing platform creat...
Esembly Inc. sells organic & sustainable cloth diapers.
Esembly Inc. sells organic & sustainable cloth ...
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innovivaâs portf...
Innoviva, Inc. (NASDAQ: INVA) is focused on roy...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Join the National Investor Network and get the latest information with your interests in mind.